Xeno Life Science Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 17-12-2024
- Paid Up Capital ₹ 5.00 M
as on 17-12-2024
- Company Age 9 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.40 M
as on 17-12-2024
- Revenue 12.90%
(FY 2020)
- Profit 6.78%
(FY 2020)
- Ebitda 31.35%
(FY 2020)
- Net Worth -93.48%
(FY 2020)
- Total Assets -0.38%
(FY 2020)
About Xeno Life Science
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹3.40 M.
Palani Sakthivel and Anbuvel serve as directors at the Company.
- CIN/LLPIN
U74900TN2015PTC099340
- Company No.
099340
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Feb 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Xeno Life Science Private Limited offer?
Xeno Life Science Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibacterial Drugs, Nutraceuticals & Dietary Supplements, Nutritional Supplements, Nutraceuticals, Ayurvedic,Herbal Products & Medicine, Ayurvedic Tablets, Antifungal Injection, Tablet & Syrup, TB, Tumor & Cancer Drugs, Anti Cancer Medicines.
Who are the key members and board of directors at Xeno Life Science?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Palani Sakthivel  | Managing Director | 23-Feb-2015 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Anbuvel | Director | 23-Feb-2015 | Current |
Financial Performance of Xeno Life Science.
Xeno Life Science Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 12.9% increase. The company also saw a slight improvement in profitability, with a 6.78% increase in profit. The company's net worth observed a substantial decline by a decrease of 93.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xeno Life Science?
In 2019, Xeno Life Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 17 Nov 2016 | ₹3.40 M | Open |
How Many Employees Work at Xeno Life Science?
Xeno Life Science has a workforce of 1 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xeno Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xeno Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
